KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) EBT: 2009-2024

Historic EBT for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to -$460.7 million.

  • Ionis Pharmaceuticals' EBT rose 10.90% to -$128.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$259.4 million, marking a year-over-year increase of 27.25%. This contributed to the annual value of -$460.7 million for FY2024, which is 37.65% down from last year.
  • Per Ionis Pharmaceuticals' latest filing, its EBT stood at -$460.7 million for FY2024, which was down 37.65% from -$334.7 million recorded in FY2023.
  • Ionis Pharmaceuticals' 5-year EBT high stood at -$30.0 million for FY2021, and its period low was -$460.7 million during FY2024.
  • Moreover, its 3-year median value for EBT was -$334.7 million (2023), whereas its average is -$351.3 million.
  • Its EBT has fluctuated over the past 5 years, first soared by 78.16% in 2021, then tumbled by 762.62% in 2022.
  • Yearly analysis of 5 years shows Ionis Pharmaceuticals' EBT stood at -$137.2 million in 2020, then skyrocketed by 78.16% to -$30.0 million in 2021, then tumbled by 762.62% to -$258.5 million in 2022, then declined by 29.48% to -$334.7 million in 2023, then crashed by 37.65% to -$460.7 million in 2024.